Navigation Links
CeNeRx BioPharma Completes $4.85 Million Financing
Date:12/9/2011

n the trial reveal regimen compliance rates of greater that 90%, with patients exhibiting therapeutic drug levels at all measured time points.  We look forward to reporting data from this TriRima Phase II trial during 2012."

Depression has long been associated with reductions in key neurotransmitters (serotonin, norepinephrine and dopamine), but only recently have researchers come to understand what causes their depletion.  New neuroimaging techniques have shown that these neurotransmitters are depleted due to the over- expression of monoamine oxidase A (MAO-A).  TriRima is the first and only medication that specifically blocks MAO-A, thereby allowing neurotransmitter levels to normalize.  This approach differs from traditional antidepressants, which seek to overcome low neurotransmitter levels primarily by concentrating the existing neurotransmitters in the gap between the neurons (the synaptic cleft), leaving the neurons themselves with a neurotransmitter deficit.  By blocking MAO-A and allowing the neurotransmitters to return to normal levels, TriRima acts to correct the neurotransmitter deficit both within the neuron and within the synaptic cleft.  TriRima's target is accordingly differentiated and upstream to the approach of most traditional classes of antidepressants, with the potential for improved efficacy.

TriRima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A. TriRima acts to normalize the levels of three key neurotransmitters that positively affect mood and anxiety, and the selectivity and reversibility of TriRima are expected to eliminate or reduce the risk of food-associated cardiovascular effects of conventional MAO inhibitors.

Separately, CeNeRx announced that it has successfully filed an IND to assess CXB909 as a potential treatment for Alzheimer's disease.  CXB909, w
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. CeNeRx BioPharma Completes $15 Million Series B Financing
4. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Windhover Announces the "Top Biopharma Projects to Watch"
7. Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
8. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announces its appointment of four new ... The workgroup leaders include:, ,     Peter ...     Erik Pupo, Specialist Leader, Deloitte Consulting LLP ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 SonaCare ... focused ultrasound (HIFU) technology, announced that its Board ... as Chief Executive Officer, President and member of ... Dr. Carol will take-on expanded responsibilities within the ... as well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... -- Investor-Edge has initiated coverage on the ... Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), Alexion ... Inc. (NASDAQ: PPHM ), and StemCells Inc. ... be accessed at: http://investor-edge.com/register . The ... a positive note as the Dow Jones Industrial Average ...
Breaking Biology Technology:WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5
... “What part of ... Barry Friedberg, MD. “Is the ASA not as smart as a fifth grader?” , ... (PRWEB) March 9, 2010 -- One ... relentless pursuit of patient safety ., , , , ,Yet no answer has been forthcoming ...
... ... ... ... ...
... ... Data-mining Platform Integrates a Variety of Data Streams into One Easy-to-use Analysis System ... (PRWEB) March 8, ... life science research, today announced Genedata Analyst™, an integrated statistical and data analysis platform ...
Cached Biology Technology:American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 2American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 2Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 4Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 5Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 6Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 2Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 3Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 4Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 5
(Date:10/17/2014)... is critical and pertinent for practicing physicians and clinicians ... epidemic. The Journal, Disaster Medicine and Public Health ... and Public Health, to surround the public, medical professionals ... moment. , On October 17, the journal published ... primer was prepared by Dr. Eric Toner, internist and ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... in the Sumatran jungle have captured first-time images of a ... into the elusive tiger,s behaviour. After a month in ... to record tigers in the Sumatran jungle caught the mother ... sniff and check out the camera trap. There are ...
... The volcanic eruptions thought responsible for Earth,s largest mass extinction ... animals 250 million years ago is still taking lives ... the first time, that the high silica content of coal ... substances in the coal to cause unusually high rates of ...
... A canine chromosome 7 locus that confers a high ... a collaboration between the Behavior Service at the Cummings ... at the University of Massachusetts Medical School and the ... findings are published in the January 2010 edition of ...
Cached Biology News:Camera traps yield first-time film of tigress and cubs 2Camera traps yield first-time film of tigress and cubs 3Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3
... work in collaboration with Pall Life Sciences ... in a variety of membrane chemistries. The ... on the Caliper TPWII, MultiDose, Prelude, and ... our Automation Certified Syringe Filters are available ...
... The Mini-PROTEAN 3 Dodeca cell with multi-casting ... of up to 12 mini format handcast (8.3 ... cm) gels. The cell requires 3.4-4.4 L of ... cooling coil that attaches to an external refrigerated ...
...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.2 ... azide. This formulation insures consistently high ...
Biology Products: